{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:38:39Z","timestamp":1795066719841,"version":"4.10.2"},"reference-count":56,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Hepatocellular carcinoma (HCC) frequently develops in patients with chronic hepatitis B and C. Early detection is critical, but current methods, including ultrasound and AFP, have suboptimal accuracy. Objectives: This study aimed to evaluate the predictive performance of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) testing, alone and in combination, for HCC development. Methods: A retrospective cohort study at a single university center included 242 CHB and 181 CHC patients. Data on demographics, clinical status, laboratory parameters, and imaging were collected, with fibrosis and steatosis assessed by FibroScan\u00ae. Serum AFP and PIVKA-II were measured, but measurements of PIVKA-II in patients receiving vitamin K antagonists were excluded from the analysis. HCC diagnosis and staging followed clinical guidelines. Cox regression and ROC analyses identified independent predictors and evaluated biomarker accuracy for HCC detection. Results: HCC incidence was comparable between cohorts (5.0% in CHB vs. 5.5% in CHC). Both AFP and PIVKA-II independently predicted HCC development in multivariate models adjusted for age and sex. The combined biomarker score (AFP \u00d7 PIVKA-II) showed superior predictive accuracy with hazard ratios of 1.38 (CHB) and 1.36 (CHC). ROC analyses demonstrated high discriminative ability for PIVKA-II (AUC ~0.81) and AFP (AUC ~0.83) in both cohorts. Additional independent predictors were chronic alcohol abuse, cirrhosis, and higher liver stiffness measurements. Specific viral factors such as HBeAg positivity and HCV subgenotype 1b were also associated with increased HCC risk. Conclusions: AFP and PIVKA-II are independent, valuable biomarkers for HCC risk in chronic hepatitis B and C. Combined use improves early detection, aiding timely treatment. These results support adding PIVKA-II to AFP in surveillance, but larger studies are needed to confirm the findings and refine cut-off values.<\/jats:p>","DOI":"10.3390\/biomedicines13112653","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:50:19Z","timestamp":1761785419000},"page":"2653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pilot Study of PIVKA-II in the Prognostic Assessment of Hepatocellular Carcinoma in Chronic Viral Hepatitis: Comparative Findings from HBV and HCV Cohorts from a Single Center in Serbia"],"prefix":"10.3390","volume":"13","author":[{"given":"Ivana","family":"Milo\u0161evi\u0107","sequence":"first","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Nikoli\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-535X","authenticated-orcid":false,"given":"Sanja","family":"Stankovi\u0107","sequence":"additional","affiliation":[{"name":"Center for Medical Biochemistry, University Clinical Center of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Filipovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Ranin","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Paunovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Simi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2097-8731","authenticated-orcid":false,"given":"Branko","family":"Beronja","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the Worldwide Hepatocellular Carcinoma: Epidemiology, Prevention and Management","volume":"12","author":"Samant","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Foglia, B., Turato, C., and Cannito, S. (2023). Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512224"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101436","DOI":"10.1016\/j.jhepr.2025.101436","article-title":"Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology","volume":"7","author":"Picchio","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10052","DOI":"10.12998\/wjcc.v9.i33.10052","article-title":"Effects of alcohol consumption on viral hepatitis B and C","volume":"9","author":"Xu","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Milosevic, I., Todorovic, N., Filipovic, A., Simic, J., Markovic, M., Stevanovic, O., Malinic, J., Katanic, N., Mitrovic, N., and Nikolic, N. (2023). HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216048"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14737140.2022.2074404","article-title":"Early detection of hepatocellular carcinoma: Roadmap for improvement","volume":"22","author":"Singal","year":"2022","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/1055-9965.EPI-20-0005","article-title":"Biomarkers for the Early Detection of Hepatocellular Carcinoma","volume":"29","author":"Parikh","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dong, L., Qiu, X., Gao, F., Wang, K., and Xu, X. (2023). Protein induced by vitamin K absence or antagonist II: Experience to date and future directions. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.189016"},{"key":"ref_11","first-page":"777","article-title":"PIVKA-II as a potential new biomarker for hepatocellular carcinoma: A pilot study","volume":"38","author":"Svobodova","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_12","first-page":"826","article-title":"PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients","volume":"29","author":"Suttichaimongkol","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hadi, H., Wan Shuaib, W.M.A., Raja Ali, R.A., and Othman, H. (2022). Utility of PIVKA-II and AFP in differentiating hepatocellular carcinoma from benign liver diseases. Medicina, 58.","DOI":"10.3390\/medicina58081015"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13027-020-00337-0","article-title":"Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation","volume":"15","author":"Si","year":"2020","journal-title":"Infect. Agents Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Feng, H., Li, B., Li, Z., Wei, Q., and Ren, L. (2021). PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08138-3"},{"key":"ref_16","first-page":"e6652","article-title":"Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing early HCC","volume":"96","author":"Park","year":"2017","journal-title":"Medicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N","article-title":"Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients","volume":"91","author":"Koike","year":"2001","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"(2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_20","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis: A Meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.iliver.2022.11.003","article-title":"Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: A large-scale real-world study","volume":"1","author":"Ge","year":"2022","journal-title":"ILIVER"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3350\/cmh.2022.0212","article-title":"Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, S., Sun, L., Yao, L., Zhu, H., Diao, Y., Wang, M., Xing, H., Lau, W.Y., Guan, M., and Pawlik, T.M. (2022). Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11175075"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.14740\/jocmr4951","article-title":"Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis","volume":"15","author":"Kobeissy","year":"2023","journal-title":"J. Clin. Med. Res."},{"key":"ref_28","first-page":"282","article-title":"Updating AFP Level in Chronic Hepatitis B to Evaluate the Risk of Hepatocellular Carcinoma Occurrence","volume":"56","author":"Kurniawan","year":"2024","journal-title":"Acta Med. Indones."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.3748\/wjg.v21.i13.3928","article-title":"Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma","volume":"21","author":"Seo","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on Global Epidemiology of Viral Hepatitis and Preventive Strategies","volume":"6","author":"Jefferies","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global Epidemiology of Alcohol-Associated Cirrhosis and HCC: Trends, Projections and Risk Factors","volume":"20","author":"Huang","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Russo, F.P., Zanetto, A., Pinto, E., Battistella, S., Penzo, B., Burra, P., and Farinati, F. (2022). Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010500"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/0115665240284347240125072555","article-title":"A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and Chronic Viral Hepatitis-Related Hepatocellular Carcinoma","volume":"25","author":"Darvishi","year":"2025","journal-title":"Curr. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular Mechanisms of Viral Hepatitis Induced Hepatocellular Carcinoma","volume":"26","author":"Lau","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural History of Hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cgh.2023.11.020","article-title":"Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma after HCV Eradication in Veterans with Cirrhosis","volume":"22","author":"John","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Davitkov, P., Hoffman, K., Falck-Ytter, Y., Wilson, B., Stojadinovikj, G., Anthony, D.D., Cohen, S.M., and Cooper, G. (2023). Increasing Liver Stiffness Is Associated with Higher Incidence of Hepatocellular Carcinoma in Hepatitis c Infection and Non-Alcoholic Fatty Liver Disease-A Population-Based Study. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280647"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cld.2024.06.007","article-title":"Alcohol and Hepatocellular Carcinoma","volume":"28","author":"Ha","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1111\/j.1440-1746.2007.05293.x","article-title":"Alcohol, Cofactors and the Genetics of Hepatocellular Carcinoma","volume":"23","author":"Yu","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.lfs.2012.10.009","article-title":"Roles of Alcohol and Tobacco Exposure in the Development of Hepatocellular Carcinoma","volume":"92","author":"Purohit","year":"2013","journal-title":"Life Sci."},{"key":"ref_42","first-page":"2279","article-title":"Mechanisms of Hepatocellular Carcinoma Progression","volume":"25","author":"Ogunwobi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1111\/j.1530-0277.1999.tb04537.x","article-title":"Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma","volume":"23","author":"Ohhira","year":"1999","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5009\/gnl14047","article-title":"The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma","volume":"9","author":"Kang","year":"2015","journal-title":"Gut Liver"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Honda, T., Ichikawa, T., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Honda, T., Yajima, H., Miyazaki, O., and Kuribayashi, Y. (2023). PIVKA II is associated with liver function, bone metabolism, and muscle function in patients with liver disease. Biomed. Rep., 20.","DOI":"10.3892\/br.2023.1690"},{"key":"ref_46","unstructured":"Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.510250344","article-title":"Hepatitis c Virus Genotypes and Risk of Hepatocellular Carcinoma in Cirrhosis: A Prospective Study","volume":"25","author":"Bruno","year":"1997","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jhep.2009.01.019","article-title":"Hepatitis c Virus Genotype 1b as a Risk Factor for Hepatocellular Carcinoma Development: A Meta-Analysis","volume":"50","author":"Raimondi","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2013.06.017","article-title":"The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia","volume":"58","author":"Milosevic","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: Global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Padarath, K., Deroubaix, A., and Kramvis, A. (2023). The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma. Viruses, 15.","DOI":"10.3390\/v15040857"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1872-034X.2007.00315.x","article-title":"A valine to phenylalanine mutation in the precore region of hepatitis B virus causes intracellular retention and impaired secretion of HBe-antigen","volume":"38","author":"Chen","year":"2008","journal-title":"Hepatol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000446240","article-title":"Hepatitis B e Antigen Expression by Hepatitis B Virus Subgenotype A1 Relative to Subgenotypes A2 and D3 in Cultured Hepatocellular Carcinoma (Huh7) Cells","volume":"59","author":"Bhoola","year":"2016","journal-title":"Intervirology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00196-19","DOI":"10.1128\/JVI.00196-19","article-title":"Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation","volume":"93","author":"Mitra","year":"2019","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/HEP.0000000000000796","article-title":"HCC Risk in Patients Who Are HBeAg-Positive and Have Chronic Hepatitis B under Long-Term Nucleos(T)Ide Analogue Therapy: New Insights from Asia","volume":"80","author":"Papatherodoridis","year":"2024","journal-title":"Hepatology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:13:57Z","timestamp":1761786837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["biomedicines13112653"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13112653","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}